Leerink last night downgraded Gossamer Bio (GOSS) to Market Perform from Outperform with a price target of $1, down from $6. The company announced “disappointing” Phase 3 PROSERA results, missing statistical significance on the primary endpoint of six-minute walk distance, the analyst tells investors in a research note. Leerink downgrades the shares pending greater clarity on the path forward for seralutinib. It sees a clouded regulatory path.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio downgraded to Underweight from Overweight at Barclays
- Gossamer Bio downgraded to Market Perform from Outperform at Leerink
- Gossamer likely to face uncertainty following Phase 3 miss, says H.C. Wainwright
- Gossamer Bio Phase 3 miss adds regulatory uncertainty, says Leerink
- Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results